Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

Abstract

Background: Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses. Molecular targeting therapy presents an opportunity to impede tumor through combination or sequential therapy, while the accurate effect is vague. Methods: The efficacy of combinations between oxaliplatin and anti-cancer molecular targeting drugs was screened. Strangely, the combined chemotherapy with oxaliplatin and saracatinib induced significantly antagonistic effects. Then the antitumor effects of combined treatment with saracatinib and oxaliplatin were confirmed in wide type HCC as well as in saracatinib-and oxaliplatin-resistant HCC. RNA sequencing was used to explore the resistance mechanism, and the roles of ATP-binding cassette transporter G1 (ABCG1) and Wnt signaling in oxaliplatin resistance were confirmed. Results: Chemotherapy with oxaliplatin and saracatinib individually induced strong anti-HCC effects, while combined or sequential treatment of HCC cells with these two drugs exhibited reduced efficacy compared to treatment with the single drugs. And it was saracatinib treatment caused oxaliplatin resistance. RNA sequencing revealed 458 genes that were altered by treatment with saracatinib and oxaliplatin. Of these, the gene encoding ABCG1 and Wnt-associated genes were significantly upregulated. Upregulation of ABCG1 and oxaliplatin resistance were associated with activation of Wnt signaling. Interference with ABCG1 expression or inhibition of Wnt signaling resulted in reversal of the saracatinib-induced oxaliplatin resistance in HCC. Conclusions: These studies demonstrated that combined or sequential chemotherapy with oxaliplatin and saracatinib reduced antitumor efficacy, and this antagonism was attributed to the activation of Wnt signaling and upregulation of ABCG1 by saracatinib.

Insights into Aflatoxin B1 Toxicity in Cattle: An In Vitro Whole-Transcriptomic Approach

“…A relationship between AFB1 exposure and ABCG1 gene expression has never been observed in the literature. This efflux transporter is a cholesterol lipid efflux pump that plays a well-known role in tumor growth, conferring chemoresistance (e.g., vs platinum-based anticancer drugs) to various malignant tumors, including HCC [123,124]. Nevertheless, the great FC we observed made us speculate a possible pivotal role of this gene in response to AFB1 exposure, thus requiring a better understand of the role of ABCG1 in AFB1 mechanistic toxicology.…”

miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma

“…ABCG1 has been demonstrated highly expressed in GBM (29,30). As a member of the ATP-binding cassette transporters, ABCG1 induces drug resistance in many cancers, including hepatocellular carcinoma and osteosarcoma (31,32), so we speculated that ABCG1 may also participate in TMZ resistance in GBM. BCL-2, one of the most common anti-apoptotic proteins, encoded by the BCL2 gene, has been widely reported to involve in TMZ resistance (33,34).…”

Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells

“…colony formation ability. Moreover, ABCG1 was recently reported to induce resistance to oxaliplatin and saracatinib and to be regulated by WNT signalling in hepatocellular carcinoma 31 .…”